Author

A. Hanly

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Jose· 1 shared A. Labadorf· 1 shared A. Xiao· 1 shared B. Tornifoglio· 1 shared C. LallyiD· 1 shared C. Lemass· 1 shared F. Agus· 1 shared F. Gibson· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

A. Jose

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Phosphotungstic acid (PTA) preferentially binds to collagen-rich regions of porcine carotid arteries and human atherosclerotic plaques using 3D micro-computed tomography (CE-μCT)

A. Hanly, R. D. Johnston, C. Lemass, A. Jose, B. Tornifoglio, C. Lally

This paper demonstrates that phosphotungstic acid (PTA) binds preferentially to collagen-rich regions in porcine carotid arteries and human atherosclerotic plaques, enabling non-destructive collagen quantification via 3D micro-CT.

bioRxiv · Jul 14, 2022 · PreprintBioengineering

The CoREST Repressor Complex Mediates Phenotype Switching and Therapy Resistance in Melanoma

M. Wu, A. Hanly, F. Gibson, K. H. Kuang, J. Kalin, S. Nocco, M. Collard, M. W. Cole, A. Xiao, F. Agus, A. Labadorf, P. A. Cole, R. M. Alani

This study identifies the CoREST repressor complex as a mediator of melanoma phenotype switching and therapy resistance, showing that its inhibitor corin can reverse resistance to BRAF inhibitors.

bioRxiv · Sep 30, 2020Cancer Biology